Hormonal
GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) provide a net health benefit for weight loss in non-diabetic adults with obesity, but only when the treatment goal is achieving ≥10% body weight loss; achieving 5% weight loss results in a net harm due to side effects.
If you are considering GLP-1 medications for weight loss without diabetes, understand that these drugs are most effective and 'worth it' if you aim to lose 10% or more of your body weight. Losing only 5% may actually result in a net negative health outcome due to side effects like nausea and vomiting. Ensure you are committed to lifestyle changes (diet and exercise) alongside the medication, and discuss your specific weight loss goals and tolerance for side effects with your doctor.
Achieving a 10% weight loss with GLP-1 RA therapy outweighed the cumulative harms, with a net benefit probability of 0.97 at year 1 and 0.91 at year 2... A 5% weight loss did not show a net benefit, with probabilities of 0.13 and 0.01 at year 1 and year 2, respectively.
Why this rating
Based on 8 RCTs with 8847 participants and meta-analysis, but relies on modeling for benefit-harm balance rather than direct long-term outcome data.
Source
GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling study
Hannah Moll et al. · EClinicalMedicine · 2024
DOI 10.1016/j.eclinm.2024.102661
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →